AR061196A1 - Compuesto de oxadiazol, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento - Google Patents

Compuesto de oxadiazol, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento

Info

Publication number
AR061196A1
AR061196A1 ARP070102281A ARP070102281A AR061196A1 AR 061196 A1 AR061196 A1 AR 061196A1 AR P070102281 A ARP070102281 A AR P070102281A AR P070102281 A ARP070102281 A AR P070102281A AR 061196 A1 AR061196 A1 AR 061196A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
unsubstituted
substituted
methyl
Prior art date
Application number
ARP070102281A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0610657.9A external-priority patent/GB0610657D0/en
Priority claimed from GB0619710A external-priority patent/GB0619710D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR061196A1 publication Critical patent/AR061196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuesto de oxadiazol de formula (1); en la que: Q representa -(CH2)n- donde n representa 3 o 4; Ra representa hidrogeno o CH3; R1 representa -NR6COR7; R2 representa hidrogeno, halogeno o alquilo C1-6; R3 representa hidrogeno, alquilo C1-6, alcoxi C1-6, halo, haloalquilo C1-6 o -O-haloalquilo C1-6; R4 y R5 representan independientemente hidrogeno, alquilo C1-6, cicloalquilo C3-6 o un anillo heterocíclico de 5 a 6 miembros que está sin sustituir o sustituido con 1, 2 o 3 sustituyentes seleccionados entre metilo o fluor; o R4 y R5, junto con el átomo de nitrogeno al que están unidos, forman un grupo heterociclilo que contiene nitrogeno que está sin sustituir o sustituido con 1, 2 o 3 sustituyentes seleccionados entre metilo o fluor; R6 representa hidrogeno; R7 representa alquilo C1-5, cicloalquilo C3-8, tetrahidropiranilo, tiofenilo, piridilo, oxazolilo, isoxazolilo, furanilo, -(CH2)marilo donde los grupos furanilo, tiofenilo, piridilo, oxazolilo, isooxazolilo o arilo pueden estar sin sustituir o sustituidos con uno a tres sustituyentes seleccionados entre halo, metilo, CF3, OCF3 u OMe, donde el grupo OMe no está presente en la posicion orto con respecto al grupo carbonilo y el grupo CF3 no está en la posicion meta o para con respecto al grupo carbonilo; m representa 0 o 1; con la condicion de que R7 no sea isopropilo; o una sal del mismo. composicion farmacéutica que los comprende y su uso para la preparacion de un medicamento util para el tratamiento de enfermedades neurologicas, trastornos psiquiátricos, trastornos relacionados con el dolor, obesidad, sépsis y trastornos gastrointestinales.
ARP070102281A 2006-05-30 2007-05-28 Compuesto de oxadiazol, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento AR061196A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0610657.9A GB0610657D0 (en) 2006-05-30 2006-05-30 Compounds
GB0619710A GB0619710D0 (en) 2006-10-05 2006-10-05 Compounds

Publications (1)

Publication Number Publication Date
AR061196A1 true AR061196A1 (es) 2008-08-13

Family

ID=38294122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102281A AR061196A1 (es) 2006-05-30 2007-05-28 Compuesto de oxadiazol, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento

Country Status (12)

Country Link
US (1) US20090105217A1 (es)
EP (1) EP2021331A1 (es)
JP (1) JP2009538865A (es)
KR (1) KR20090014223A (es)
AR (1) AR061196A1 (es)
AU (1) AU2007267170A1 (es)
BR (1) BRPI0711779A2 (es)
CA (1) CA2653771A1 (es)
EA (1) EA200870591A1 (es)
PE (1) PE20080311A1 (es)
TW (1) TW200811155A (es)
WO (1) WO2007138033A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0723719D0 (en) * 2007-12-04 2008-01-16 Glaxo Group Ltd Compounds
GB0723815D0 (en) * 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
ATE556998T1 (de) * 2008-08-12 2012-05-15 Hoffmann La Roche Salicylamidderivate als nikotinische alpha-7- modulatoren
MX2011001844A (es) * 2008-09-02 2011-04-05 Neurosearch As Derivados de triazol y su uso como moduladores del receptor de acetilcolina nicotinico.
WO2011079439A1 (en) * 2009-12-30 2011-07-07 Zannan Scitech Co., Ltd. Highly active metathesis catalysts selective for romp and rcm reactions
CN110709394A (zh) * 2017-03-31 2020-01-17 中美博瑞纳制药有限公司 可用作alcat1抑制剂的化合物
CN111960983A (zh) * 2020-08-31 2020-11-20 南通大学 一种n-甲基-3-(1-甲基吡咯烷-3-基)丙-1-胺及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220741B2 (en) * 2002-09-30 2007-05-22 Neurosearch A/S 1,4-diazabicycloalkane derivatives, their preparation and use

Also Published As

Publication number Publication date
KR20090014223A (ko) 2009-02-06
US20090105217A1 (en) 2009-04-23
WO2007138033A1 (en) 2007-12-06
CA2653771A1 (en) 2007-12-06
EA200870591A1 (ru) 2009-06-30
PE20080311A1 (es) 2008-05-23
BRPI0711779A2 (pt) 2011-11-29
AU2007267170A1 (en) 2007-12-06
EP2021331A1 (en) 2009-02-11
JP2009538865A (ja) 2009-11-12
TW200811155A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
AR061196A1 (es) Compuesto de oxadiazol, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento
RU2475478C2 (ru) Соединения для лечения пролиферативных расстройств
RU2017126128A (ru) Конденсированные бициклические соединения для лечения заболевания
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR045651A1 (es) Derivados de tiazol como moduladores del receptor de cannabinoide
JP2016506960A5 (es)
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
RU2008146993A (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
ATE537169T1 (de) Piperidin- und piperazinderivate als p2x3- antagonisten
RU2017123114A (ru) 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов
RS54708B1 (en) ARYLETINYL DERIVATIVES
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
AR060054A1 (es) Inhibidores de c-met protein quinasas. composiciones farmaceuticas.
RU2017126990A (ru) Замещенные бензольные соединения
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
AR054232A1 (es) Derivados de piridina -2- carboxamida como antagonistas de mglur5
AR057244A1 (es) Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes.
RU2010102529A (ru) Способ борьбы с вредителями животных
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
CO6140059A2 (es) Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3)
BRPI0907122B8 (pt) compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR082827A1 (es) Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson
AR053153A1 (es) Derivados de pirazina -2- carboxamida como antagonistas de mglur5

Legal Events

Date Code Title Description
FB Suspension of granting procedure